Breast cancer

BC · Oncology · 12 drugs · 15 indications

Cancer originating in breast tissue. Subtypes include HR+, HER2+, and triple-negative.
Competitive Landscape (12 drugs)
DrugCompanyMechanismModalityRouteStage
GiredestrantROG.SWSERDOral SERDOralFILED
camizestrantAZNOral SERDSmall moleculeORALPHASE3
TruqapAZNAKT inhibitorSmall moleculeORALAPPROVED
EnhertuAZN, DSNKYHER2-directed (DXd payload)ADCIVAPPROVED
DatrowayAZN, DSNKYTROP2-directed (DXd payload)ADCIVAPPROVED
VerzenioLLYCDK4/6 inhibitorSmall moleculeORALAPPROVED
KisqaliNVSCDK4/6 inhibitorSmall moleculeOralAPPROVED
PerjetaROG.SWHER2 dimerization inhibitorAntibodyIVAPPROVED
HerceptinROG.SWHER2 antagonistAntibodyIV/SCAPPROVED
KadcylaROG.SWHER2-targeted (DM1 payload)ADCIVAPPROVED
PhesgoROG.SWHER2 dual blockadeAntibodySCAPPROVED
LynparzaAZN, MRKPARP inhibitorSmall moleculeORALAPPROVED
Indications (15)
HER2+ Breast Cancer (neoadj)
Perjeta APPROVED
ER+ Breast Cancer (Metastatic)
Giredestrant PHASE3
HER2+ Breast Cancer
Herceptin APPROVEDPhesgo APPROVEDEnhertu APPROVED
HER2+ mBC
Kadcyla APPROVEDPerjeta APPROVED
First-line HR+/HER2- mBC
HER2-low breast cancer
Enhertu APPROVED
Breast cancer (germline BRCA-mutated)
Lynparza APPROVED
HR-positive HER2-negative breast cancer
Truqap APPROVEDDatroway APPROVED
ER-positive HER2-negative advanced breast cancer
camizestrant PHASE3
HER2+ eBC (adj)
Kadcyla APPROVED
ER+ Breast Cancer (Adjuvant)
Giredestrant FILED
HER2-ultralow breast cancer
Enhertu APPROVED
HR+ HER2- Breast Cancer
Verzenio APPROVED
HR+/HER2- metastatic breast cancer
Kisqali APPROVED
HR+/HER2- early breast cancer
Kisqali APPROVED
Upcoming Catalysts
Giredestrant - 1L mBC - Ph3 - Topline (persevERA)CLINICAL
ROG.SWH1 2026
Datroway - TROP2 Biomarker-Directed - Ph3 - Start (TROPION-Lung17)CLINICAL
DSNKYJan 2026
Enhertu + Pertuzumab - 1L HER2+ mBC - FDA Approval (DESTINY-Breast09)REGULATORY
DSNKYJan 23, 2026
Datroway - 1L mTNBC (PD-L1 neg) - FDA ApprovalREGULATORY
DSNKYQ2 2026
Enhertu - Global Sales TrajectoryCOMMERCIAL
DSNKY2026
Giredestrant - Early BC - FDA/EMA ApprovalREGULATORY
ROG.SWH2 2026
Camizestrant - HR+ Breast - Ph3 - Topline (SERENA-4)CLINICAL
AZNH2 2026
Datroway + Imfinzi - 1L NSCLC - Ph3 - Topline (AVANZAR)CLINICAL
DSNKYH2 2026
Datroway + Keytruda - 1L NSCLC PD-L1 High - Ph3 - Topline (TROPION-Lung08)CLINICAL
DSNKYH2 2026
Datroway + Keytruda - 1L NSCLC PD-L1 Low - Ph3 - Topline (TROPION-Lung07)CLINICAL
DSNKYH2 FY2026
Data from Supabase · Updated 2026-03-24